Takeda Pharmaceutical has filed a patent for methods of treating schizophrenia using Compound (I) and its pharmaceutically acceptable salts. The patent claims that administering more than 80 mg of Compound (I) to a patient in need can effectively treat schizophrenia. GlobalData’s report on Takeda Pharmaceutical gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Takeda Pharmaceutical, Cancer treatment biomarkers was a key innovation area identified from patents. Takeda Pharmaceutical's grant share as of September 2023 was 46%. Grant share is based on the ratio of number of grants to total number of patents.
Treating schizophrenia with a specific compound in high dosage
A recently filed patent (Publication Number: US20230310441A1) describes a method of treating schizophrenia using a specific compound, referred to as Compound (I), and its pharmaceutically acceptable salts. The method involves administering more than 80 mg of Compound (I) to a patient in need of treatment. The patent also claims that higher doses, such as more than 100 mg, 120 mg, or 160 mg, can be administered for more effective treatment.
The method aims to achieve a mean Cmax (maximum concentration) of at least 500 ng/mL in the patient, but not exceeding 2500 ng/mL. The compound can be administered orally, either in tablet form or as an oral suspension. The patent also suggests that the compound can be administered with or without food.
In addition to Compound (I), the method may involve administering at least one additional active pharmaceutical ingredient, particularly antipsychotics. The treatment is intended to address negative symptoms of schizophrenia, such as anhedonia, loss of motivation, and reduced interest in social interaction, as well as cognitive symptoms, including impaired verbal memory, working memory, motor function, attention and processing speed, verbal fluency, and executive function.
The method also aims to modulate reward anticipation related brain activity, increase ventral striatal activity during reward anticipation, modulate cerebral blood flow, and modulate dopamine release in the patient.
The patent also describes a loading dose regimen, where a higher dose of Compound (I) is administered initially, followed by weekly maintenance doses. The loading dose can be more than 20 mg, 40 mg, 80 mg, 120 mg, or 160 mg, depending on the patient's needs. The loading dose is effective in achieving a mean Cmax of at least 250 ng/mL, but not exceeding 2500 ng/mL. The weekly maintenance dose is typically half the loading dose and can be administered orally, in tablet form or as an oral suspension.
The patent also covers a pharmaceutical composition containing more than 80 mg of Compound (I) or its pharmaceutically acceptable salts. Higher doses, such as more than 100 mg, 120 mg, or 160 mg, can also be included in the composition. The pharmaceutical composition can be in the form of tablets or an oral suspension.
It is important to note that the information provided is based solely on the claims made in the filed patent and does not include any additional research or clinical data.
To know more about GlobalData’s detailed insights on Takeda Pharmaceutical, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
